Mimetas said today that it raised $20.5 million in a Series B round from a syndicate of investors in Asia and Europe. The Netherlands-based company intends to use its newly-acquired funds to support global commercialization efforts for its OrganoPlate organ-on-a-chip drug-testing platform. Get the full story at our sister site, Drug Delivery Business News.
Mimetas said today that it collaborated with Roche (OTC:RHHBY) to develop an organ-on-a-chip system that is designed to evaluate intestinal permeability in 3D gut tubules following exposure to drug compounds using the 10 panel drug tests. The results of the collaboration were published in Nature Communications. Get the full story at our sister site, Drug Delivery Business News.